Quarterly ResultMay 12, 2026, 09:32 AM
IceCure Q1 Revenue +26% to $911K; U.S. Sales +31%
AI Summary
IceCure Medical reported strong first-quarter 2026 financial results, with global revenue increasing 26% to $911,000, driven by substantial 84% growth in North America and 31% in U.S. sales. The company saw a 46% increase in active U.S. customer accounts for its ProSense system following FDA clearance, alongside positive clinical updates and expanding reimbursement. Despite an increased net loss of $4.27 million, the company is optimistic about accelerating adoption and market penetration, planning to expand its U.S. sales footprint.
Key Highlights
- Global revenue rose 26% to $911,000 in Q1 2026 vs. Q1 2025.
- North America sales increased 84% in Q1 2026.
- U.S. sales grew 31% in Q1 2026.
- Gross profit increased 35% to $295,000, with gross margin at 32% in Q1 2026.
- Active U.S. customer accounts using ProSense increased 46% post-FDA clearance.
- Net loss for Q1 2026 was $4,274,000, or $0.06 per share.
- Cash and cash equivalents totaled $8,115,000 as of March 31, 2026.